Stock Events

Stock Events

Syndax Pharmaceuticals 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11MayExpected
Q4 2025
Next
-0.66
-0.61
-0.55
-0.49
Expected EPS
-0.5364683376
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1T3.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap298.84B
Merck & Co., Inc. competes in the oncology space with its range of cancer treatments, potentially overlapping with Syndax's focus on cancer therapeutics.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol-Myers Squibb Company offers a portfolio of cancer drugs, directly competing with Syndax Pharmaceuticals in the oncology market.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca PLC has a strong presence in developing cancer treatments, including therapies that may compete with Syndax's pipeline.
Pfizer
PFE
Mkt Cap161.09B
Pfizer Inc. has a broad range of oncology products that could compete with Syndax Pharmaceuticals' cancer therapies.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, Inc. is involved in the development of oncology and hematology drugs, areas where Syndax is also aiming to make an impact.
AMGEN
AMGN
Mkt Cap187.56B
Amgen Inc. competes in the biopharmaceutical space, focusing on innovative therapies that could rival Syndax's cancer treatment solutions.
Novartis
NVS
Mkt Cap297.32B
Novartis AG has a diversified portfolio in oncology, potentially competing with Syndax Pharmaceuticals in multiple areas of cancer treatment.
Roche
RHHBY
Mkt Cap321.08B
Roche Holding AG, through its pharmaceuticals division, develops cancer drugs that could be in direct competition with Syndax's offerings.
Incyte
INCY
Mkt Cap19.09B
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, including cancer treatments that may compete with Syndax.
Exelixis
EXEL
Mkt Cap11.76B
Exelixis, Inc. is focused on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers, directly competing with Syndax Pharmaceuticals.

About

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Show more...
CEO
Mr. Michael A. Metzger M.B.A.
Employees
298
Country
Germany
ISIN
US87164F1057

Listings

MU
DE
1T3.MU
F
DE
1T3.F
STU
DE
1T3.STU
XNAS
US
SNDX

0 Comments

Share your thoughts

FAQ

What is Syndax Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Syndax Pharmaceuticals stocks are traded under the ticker 1T3.MU.
When is the next Syndax Pharmaceuticals earnings date?▼
Syndax Pharmaceuticals is going to release the next earnings report on May 11, 2026.
What were Syndax Pharmaceuticals earnings last quarter?▼
1T3.MU earnings for the last quarter are -0.66 EUR per share, whereas the estimation was -0.49 EUR resulting in a -33.55% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Syndax Pharmaceuticals have?▼
As of April 12, 2026, the company has 298 employees.
In which sector is Syndax Pharmaceuticals located?▼
Syndax Pharmaceuticals operates in the Health & Wellness sector.
When did Syndax Pharmaceuticals complete a stock split?▼
Syndax Pharmaceuticals has not had any recent stock splits.
Where is Syndax Pharmaceuticals headquartered?▼
Syndax Pharmaceuticals is headquartered in New York, Germany.